^
Association details:
| Biomarker: | TSC2 mutation |
|---|---|
| Cancer: | Peripheral T-cell Lymphoma |
| Drug: | Aliqopa (copanlisib) (PIK3CA inhibitor, PI3Kδ inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
COMBINATION TREATMENT WITH COPANLISIB, A PI3K INHIBITOR, AND GEMCITABINE IN RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMAS (RR-PTCL); A MULTICENTER, OPEN-LABEL, PHASE 1/2 TRIAL (COSMOS TRIAL)
Published date:
06/12/2020
Excerpt:
The genes exclusively mutated in the responsive group were IDH2, RHOA, and TSC2....The study shows that Cop can be safely combined with Gem and the combination regimen is active with manageable toxicities in pts with RR-PTCLs.
Secondary therapy:
gemcitabine
Trial ID:
